Raiffeisen Informatik Simplifies Network Operations with Juniper Networks to Provide Better User Experience for Financial Customers
Juniper Networks, (NYSE: JNPR), a leader in secure, AI-driven networks, today announced that Raiffeisen Informatik (R-IT), a provider of comprehensive IT-services for financial service and insurance providers, has deployed Juniper Apstra data center solutions to modernize and automate its network infrastructure to provide exceptional services for its customers.
R-IT works consistently and emphatically to provide high-quality services and fail-safe infrastructures to its customers 24/7. R-IT’s long standing customers rely on the provider’s consistent and innovative solutions that significantly increase their flexibility as well as R-IT’s added value, from lending business and receivables management through securities settlement, to data management and digitalized accounting.
Juniper Apstra, the company’s data center solution for automation, will simplify planning, design and operations for R-IT’s network teams, reducing configuration errors for a more predictable data center network while maximizing both reliability and speed to create a better user experience.
News Highlights:
- R-IT can simplify and automate its operations from design to deployment (Day 0 and 1) through everyday operations and assurance with the turnkey Apstra System.
- Apstra usesroot-cause analysis to reduce the duration of network issues and shorten maintenance time with maintenance-mode capabilities. With Apstra, R-IT can dramatically reduce the time needed to deliver new network services, achieving faster time to deployment and time to resolution.
- With automated, flexible and simplified operations, R-IT can push out new application updates and services with minimal downtime for smooth, consistent user experiences.
- By automating the network lifecycle, IT resources can be used more efficiently, freeing up the company’s talented IT staff for strategic work. Pressure on hiring infrastructure and operations staff is expected to be relieved.
- With its open, flexible architecture, Apstra enables R-IT to deploy and operate multivendor networks with the ease and simplicity of a single-vendor network.
- In R-IT’s data centers, Juniper QFX Series Switches provide a flexible network fabric with industry-leading throughput and scalability, an extensive routing stack, the open programmability of the Junos® OS and a broad set of EVPN-VXLAN and IP fabric capabilities.
Supporting quotes:
“Our deep industry knowledge and strong foundation help ensure that our customers receive the best IT service at the highest levels of security, performance and availability, so they can concentrate on their core processes. Juniper Apstra provides an automated network platform that allows us to serve our customers with greater business agility.”
- Michael Linhart, CEO, Raiffeisen Informatik
“Financial institutions are looking for operational services that are reliable, resilient and agile. R-IT is providing critical services to its customers 24/7, and Juniper supports that with our objective to fully automate changes and assure continuous operation. With intent-based networking automation to help modernize and automate R-IT’s complete data center, Apstra increased reliability without more headcounts.”
- Mike Bushong, Vice President, Data Center Product Management, Juniper Networks
Additional resources:
- Success Story: R-IT
- Follow Juniper Networks online: Facebook | Twitter | LinkedIn
- Juniper Blogs and Community: J-Net
About Juniper Networks
Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on Twitter, LinkedIn and Facebook.
Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.
category-enterprise
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220315005126/en/
Contact information
Pelin Murphy
Juniper Networks
+44 (0) 1372 385 686
pelin@juniper.net
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ilsong Educational Foundation Chairman Dai-Won Yoon Wins Linnaeus Medal as the First in Asia2.6.2023 11:00:00 CEST | Press release
On May 30, Chairman Dai-Won Yoon of Ilsong Educational Foundation received the Linnaeus Medal from Uppsala University at Hallym University. This makes him the first person from Asia to receive the award. Ilsong Educational Foundation operates Hallym University and Hallym University Medical Center. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230531005495/en/ Chairman Dai-Won Yoon (left) of Ilsong Educational Foundation received Linnaeus Medal as the 1st in Asia (Photo: Hallym University) Chairman Yoon is the honoree of 2020. The award ceremony, which had been postponed due to COVID-19, was held this year with a delegation led by Vice Chancellor Anders Hagfeldt of Uppsala University visiting Korea. The Linnaeus Medal to commemorate Carl Linnaeus, a Swedish botanist, is awarded annually by Uppsala University to a person who has made a significant contribution to the field of science. Chairman Yoon was honored for his work in
10 th Annual World Patient Safety, Science & Technology Summit Begins2.6.2023 08:15:00 CEST | Press release
Day one of the 10th Annual World Patient Safety, Science & Technology Summit presented by the Patient Safety Movement Foundation (PSMF) saw global leaders across the world of patient safety call for an increased urgency in addressing the issue of preventable harm within healthcare. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601006140/en/ Joe Kiani, founder of the Patient Safety Movement Foundation, speaks at the 10th Annual World Patient Safety, Science & Technology Summit in Newport Beach, California. (Photo: Business Wire) Celebrating the PSMF’s 10th anniversary, Dr. Michael Ramsay, chief executive officer of the PSMF, reflected on the role that the increasing availability of hospital data on medical errors could play in reducing harm. “I’m very optimistic that we’re really going to see a difference in healthcare,” he said. “Technology is changing. We’re now getting real data. We know what the outcomes are in hospit
Autel Energy Holds Partner Summit in Amsterdam, Mapping Out Europe Strategy2.6.2023 08:00:00 CEST | Press release
Autel Energy, a leading provider of EV charging products and services, successfully hosted the Autel Partner Summit at Muziekgebouw in Amsterdam from May 31 to June 1, 2023. The event not only showcased Autel’s visionary Europe strategy for the next two years but also provided partners opportunities to gain insights into the company's vision, and learn about Autel’s new products. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230525005428/en/ A quick afternoon bite with the Autel partners. (Photo: Business Wire) The Partner Summit helped Autel Energy to strengthen its partnerships in Europe and highlighted its collaborations with key clients. Notable partners in attendance included Maxicharger AC clients such as Sevadis and Deta, as well as Maxicharger DC clients such as Floading, Gasgas, and eWays. The company also partnered with CPO clients like Fastway and Powerdo, as well as energy companies like Enefit. The Summit was d
PL BioScience and Macopharma enter into a Patent License and Assignment Agreement regarding Human Platelet Lysate (HPL) cell culture supplements.2.6.2023 07:22:00 CEST | Press release
PL BioScience GmbH, a German life science company specializing in the production and development of Human Platelet Lysate (HPL) for cell expansion, today announced a Patent License and Assignment Agreement with the French company Macopharma S.A.S. As a result of the Agreement, PL BioScience will hereby accept a worldwide license under the patents filed by Macopharma, with a right to sublicense (through multiple tiers), for the duration of the license period. In addition to the Patent License and Assignment Agreement, Macopharma will introduce PL BioScience to their current HPL customers, and thanks to a comprehensive comparative evaluation showing equivalence of HPL products from PL BioScience, Macopharma HPL customers will have the opportunity to transfer their future orders to PL BioScience with minimal disruption. About PL BioScience: Located in Aachen in Germany, PL BioScience GmbH is a life science company specializing in the production and development of Human Platelet Lysate (HP
AOP Health: Completed Study Strengthens Clinical Development Program for ropeginterferon alpha 2b (Besremi®) in polycythaemia vera2.6.2023 04:00:00 CEST | Press release
With the publication of the final results from the LOW-PV study in the New England Journal of Medicine Evidence conducted by Fondazione per la Ricerca dell'Ospedale di Bergamo (FROM) under the leadership of Professor Tiziano Barbui, AOP Health announces an important advancement reinforcing its clinical development program for ropeginterferon alpha-2b (BESREMi®) in polycythaemia vera (PV), a rare blood cancer. The academic LOW-PV study supported and funded by AOP Health and public organizations in Italy complements a series of trials performed by AOP Health over more than 10 years to achieve marketing authorization in Europe and the Middle East. With these clinical studies, including PEGINVERA,PROUD-PV, and CONTINUATION-PV, AOP Health opened a new area of treatment options for patients suffering from PV. A further study (PEN-PV) was performed to develop a pen for self-injection allowing ease of self-administration, exact dosing and minimal waste of the medical product. AOP Health’s comp
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom